久久精品欧美日韩精品,中文字幕av区四区三区二区一区,久久久久久精品免费免费麻辣,欧美日韩免费高清大片

Cell Line Name：

Host Cell:

BA/F3

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS+2ug/ml puromycin

Mycoplasma Status:

Negative

NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013).

a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013).

b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013).

c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013)

1. WB of LMNA-NTRK1/BaF3 expression

2. Sanger of LMNA-NTRK1/BaF3 expression

Figure 2. Sanger Sequencing of LMNA-NTRK1/BaF3

3. Anti-proliferation assay

Figure 3. Anti-proliferation assay of two reference compounds on the LMNA-NTRK1/BaF3 Stable Cell Line